BML Capital Management LLC Cuts Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

BML Capital Management LLC decreased its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 42.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 228,500 shares of the biopharmaceutical company’s stock after selling 169,780 shares during the period. Vanda Pharmaceuticals comprises 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 19th biggest position. BML Capital Management LLC owned approximately 0.39% of Vanda Pharmaceuticals worth $1,072,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new stake in shares of Vanda Pharmaceuticals during the third quarter worth about $143,000. China Universal Asset Management Co. Ltd. increased its stake in Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 4,374 shares during the period. ORG Wealth Partners LLC acquired a new stake in Vanda Pharmaceuticals during the 3rd quarter worth approximately $40,000. SG Americas Securities LLC boosted its position in Vanda Pharmaceuticals by 88.5% in the 3rd quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 9,580 shares during the period. Finally, Nantahala Capital Management LLC grew its stake in shares of Vanda Pharmaceuticals by 57.3% in the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock worth $9,003,000 after acquiring an additional 580,265 shares in the last quarter. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VNDA has been the topic of several analyst reports. StockNews.com started coverage on Vanda Pharmaceuticals in a research note on Saturday. They issued a “hold” rating on the stock. Cantor Fitzgerald boosted their price objective on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Finally, HC Wainwright started coverage on shares of Vanda Pharmaceuticals in a report on Thursday, October 31st. They issued a “buy” rating and a $18.00 target price on the stock.

Vanda Pharmaceuticals Stock Performance

NASDAQ VNDA traded up $0.12 during trading on Tuesday, reaching $5.46. 204,424 shares of the company’s stock were exchanged, compared to its average volume of 1,302,546. The stock has a market cap of $318.26 million, a P/E ratio of -19.07 and a beta of 0.77. Vanda Pharmaceuticals Inc. has a 1 year low of $3.32 and a 1 year high of $6.75. The company has a 50 day moving average price of $4.79 and a two-hundred day moving average price of $5.25.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.